<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692312</url>
  </required_header>
  <id_info>
    <org_study_id>AMO-02-MD-2-003</org_study_id>
    <secondary_id>2016-004623-23</secondary_id>
    <nct_id>NCT03692312</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy</brief_title>
  <official_title>A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMO Pharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMO Pharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of
      patients (aged 6 to 16 years) diagnosed with Congenital Myotonic Dystrophy (Congenital DM1).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo controlled study of weight adjusted dose 1000
      mg/day tideglusib versus placebo in the treatment of children and adolescents 6-16 years of
      age with Congenital DM1.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS)</measure>
    <time_frame>22 weeks</time_frame>
    <description>The Clinician-Completed Congenital DM1 Scale is an 11-item rating scale completed by the clinician that scores the symptom severity of domains that are clinically relevant in Congenital DM1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression- Improvement Scale (CGI-I) scores</measure>
    <time_frame>22 weeks</time_frame>
    <description>The clinician administered CGI-I rates how much the subject's illness has improved or worsened relative to a baseline state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Top 3 Caregiver Concerns Visual Analogue Scale (VAS) score</measure>
    <time_frame>22 Weeks</time_frame>
    <description>The Top 3 concerns VAS allows caregivers to identify their main three causes of concern, related to the subject's myotonic dystrophy, rather than these being pre-specified within a scale and then rating how these concerns have changed at specific time-points during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Completed Congenital DM1 Rating Scale (CC-CDM1-RS)</measure>
    <time_frame>22 weeks</time_frame>
    <description>The Caregiver-Completed Congenital DM1 Scale is a caregiver assessment of the subject on symptoms that may occur in individuals with CDM1. There are a total of 11 clinically relevant symptoms that the caregiver is asked to rate the severity of.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Severity Scale (CGI-S)</measure>
    <time_frame>22 weeks</time_frame>
    <description>The Clinical Global Impression - Severity Scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the subject's illness at the time of assessment, relative to the clinician's past experience with subjects who have the same diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events (AEs), including serious adverse events (SAEs), between Screening to end of study.</measure>
    <time_frame>22 to 28 weeks</time_frame>
    <description>Adverse events may be volunteered spontaneously by the subject, or discovered as a result of general, non-leading questioning by physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal findings in objective assessments (e.g. laboratory values, ECGs, vital signs and bone mineral density) between Screening and end of study.</measure>
    <time_frame>22 to 28 weeks</time_frame>
    <description>Abnormal laboratory findings (e.g. hematology, liver function, biochemistry, urinalysis) or other abnormal assessments (e.g. ECGs, vital signs) that are judged by the Investigator as clinically significant will be recorded as AEs or SAEs if they meet the definition of an AE. The Investigator will exercise his or her medical and scientific judgment in deciding whether an abnormal laboratory finding or other abnormal assessment is clinically significant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Congenital Myotonic Dystrophy</condition>
  <arm_group>
    <arm_group_label>Tideglusib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weight adjusted tideglusib, orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tideglusib</intervention_name>
    <description>Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily</description>
    <arm_group_label>Tideglusib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo formulation</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tideglusib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female children and adolescents aged ≥6 years and ≤16 years

          2. Diagnosis of Congenital DM1 (also known as Steinert's disease)

               -  Diagnosis must be genetically confirmed

               -  One or more of the following clinically relevant (e.g. requiring medical
                  intervention) signs or symptoms was evident within the first week after birth:

                    -  Hypotonia

                    -  Generalized weakness

                    -  Respiratory insufficiency

                    -  Feeding difficulties

                    -  Clubfoot or another musculoskeletal deformity

          3. Subject must be able to walk and complete the 10-meter walk-run test
             (orthotics/splints allowed, forearm crutches are not allowed)

          4. Written, voluntary informed consent must be obtained before any study related
             procedures are conducted.

               -  Where a parent or LAR provides consent, there must also be assent from the
                  subject

          5. Subject's caregiver must be willing and able to support participation for duration of
             study

          6. Subject must be willing and able to comply with the required food intake restrictions
             as outlined per protocol

        Exclusion Criteria:

          1. Not able to walk; (full time wheel chair use)

          2. Body mass index (BMI) less than 13.5 kg/m² or greater than 40 kg/m²

          3. New or change in medications/therapies within 4 weeks prior to Screening

          4. Use of strong CYP3A4 inhibitors (e.g clarithromycin, telithromycin, ketoconazole,
             itraconazole, posaconazole, nefazodone, idinavir and ritonavir) within 4 weeks prior
             to Baseline

          5. Concurrent use of drugs metabolized by CYP3A4 with a narrow therapeutic window (e.g.
             warfarin and digitoxin)

          6. Current enrollment in a clinical trial of an investigational drug or enrollment in a
             clinical trial of an investigational drug in the last 6 months

          7. Existing or historical medical conditions or complications (e.g. neurological,
             cardiovascular, renal, hepatic, endocrine, gastrointestinal or respiratory disease)
             which would cause the investigator to conclude that the subject will not be able to
             perform the study procedures or assessments or would confound interpretation of data
             obtained during assessment

          8. Hypersensitivity to tideglusib and its excipients including allergy to strawberry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph P Horrigan, MD</last_name>
    <role>Study Director</role>
    <affiliation>AMO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>310-825-3264</phone>
    </contact>
    <investigator>
      <last_name>Perry Shieh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stanford Neuromuscular Research</last_name>
      <phone>650-725-4341</phone>
      <email>neuromuscularresearch@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John W Day, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bryn Miller, BSN, RN</last_name>
      <phone>319-335-5836</phone>
      <email>bryn-miller@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont University</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Beth Kring</last_name>
      <phone>248-898-7289</phone>
      <email>elizabeth.kring@beaumont.org</email>
    </contact>
    <investigator>
      <last_name>Eileen McCormick, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>James Hilbert</last_name>
      <phone>585-273-5590</phone>
      <email>james_hilbert@URMC.Rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeanne Dekdebrun</last_name>
      <phone>585-276-4611</phone>
      <email>jeanne_Dekdebrun@URMC.Rochester.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Johanna Hamel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emma Ciafaloni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Monahan</last_name>
      <phone>412-692-5176</phone>
      <email>jennifer.monahan@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Hoba Abdel-Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Specialty Group, PLLC, Division of Child &amp; Adolescent Neurology, Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Terrie Conklin, RN, CCRC</last_name>
      <phone>757-668-9356</phone>
      <email>terrie.conklin@CHKD.ORG</email>
    </contact>
    <investigator>
      <last_name>Crystal Proud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University - Department of Neurology. Muscular Dystrophy Translational Research Program.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Danielle Frazier</last_name>
      <phone>804-277-9244</phone>
      <email>danielle.frazier@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Nicholas Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital London Health Sciences Centre (LHSC)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Rhiannon Hicks</last_name>
      <phone>519-685-8441</phone>
      <email>rhiannon.hicks@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Craig Campbell, MD, MSc, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Rosa Ramos</last_name>
      <email>rramos@cheo.on.ca</email>
    </contact>
    <investigator>
      <last_name>Hugh McMillan, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle University</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE2 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Angela Green</last_name>
      <phone>0191 208 3105</phone>
      <email>Angela.Green@newcastle.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Grainne Gorman, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tideglusib</keyword>
  <keyword>AMO-02-MD-2-003</keyword>
  <keyword>Congenital Myotonic Dystrophy</keyword>
  <keyword>Myotonic Dystrophy</keyword>
  <keyword>Dystrophia Myotonica</keyword>
  <keyword>Myotonia Atrophica</keyword>
  <keyword>Myotonia Dystrophica</keyword>
  <keyword>Myotonic Dystrophy, Congenital</keyword>
  <keyword>Steinert Disease</keyword>
  <keyword>Steinert Myotonic Dystrophy</keyword>
  <keyword>Steinert's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

